Nanoparticles News and Research

RSS

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Researchers from Rice University's Laboratory for Nanophotonics (LANP), the radiology department at Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center are preparing to test a combined approach for diagnosing and treating pancreatic cancer with a specially engineered nanoparticle.

19 Oct 2010

Silver studded bacteria could help treat common cold and flu

Finally scientists may have found a potential cure for common cold. They have found “silver bullets” in yogurt that could destroy viruses and provide a cure for the flu and common cold.

18 Oct 2010

NIST mini-sensors track human heartbeat

Researchers from the National Institute of Standards and Technology (NIST) and the German national metrology institute have used NIST's miniature atom-based magnetic sensor to successfully track a human heartbeat, confirming the device's potential for biomedical applications.

15 Oct 2010

Stony Brook professor receives 2010 NIH Director's New Innovator Award

Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award.

14 Oct 2010

Researchers develop new approach to treat inflammatory bowel disease

Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.

11 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

C-CCNE receives grant to improve cancer treatment using nanotechnology

The National Cancer Institute has awarded a five-year, $13.6 million grant to the University of North Carolina at Chapel Hill's Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) based at the UNC Lineberger Comprehensive Cancer Center, for research to improve the diagnosis and treatment of cancer through applying/using advances in nanotechnology.

28 Sep 2010

Sunscreens containing nanoparticles alarms consumer group

The consumer group CHOICE is demanding more honesty from sunscreen manufacturers after many leading brands were found to contain nanoparticles. There is controversy as to whether the particles, which are smaller than 100 billionths of a meter, can penetrate the skin and have harmful side-effects, says CHOICE. However many of these sunscreens contain nano-grade titanium dioxide and zinc oxide that enable them to offer the same sun protection but go on clear and with less skin residue.

27 Sep 2010

Researchers develop magnetic nanoparticles for metallic implant drug delivery

If a drug can be guided to the right place in the body, the treatment is more effective and there are fewer side-effects. Researchers at Lund University in Sweden have now developed magnetic nanoparticles that can be directed to metallic implants such as artificial knee joints, hip joints and stents in the coronary arteries.

26 Aug 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

NJIT researchers awarded 15 new U.S. patents for research programs

NJIT researchers were awarded 15 new U.S. patents this past year, increasing the total number of issued patents for NJIT to 97. More than 150 applications are in process. With projected research expenditures greater than $90 million for 2010-11, NJIT ranks as a leader in size and growth of research programs among technological universities. The patents were awarded from July 1, 2009-June 30, 2010. Specifics follow.

24 Aug 2010

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Arizona State University researchers have demonstrated a way to dramatically simplify testing patients for infectious diseases and unhealthy protein levels.New testing instrumentation developed by Antonia Garcia and John Schneider promises to make the procedure less costly and produce results in less time.

24 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries.

20 Aug 2010

Nanoparticles News and Research

Dicerna secures $4 million in second closing of Series B equity financing

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Silver studded bacteria could help treat common cold and flu

NIST mini-sensors track human heartbeat

Stony Brook professor receives 2010 NIH Director's New Innovator Award

Researchers develop new approach to treat inflammatory bowel disease

Gymnemic acid nanocrystals could help develop soluble drug compounds

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

C-CCNE receives grant to improve cancer treatment using nanotechnology

Sunscreens containing nanoparticles alarms consumer group

Researchers develop magnetic nanoparticles for metallic implant drug delivery

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

NJIT researchers awarded 15 new U.S. patents for research programs

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News